Contineum Therapeutics, Inc.
Business
Contineum Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule therapies targeting neuroinflammation and fibrotic indications. Its lead asset PIPE-791, a brain-penetrant LPA1 receptor antagonist, is in Phase 2 development for idiopathic pulmonary fibrosis and Phase 1b trials for chronic pain. The company's second candidate, PIPE-307, a selective M1 receptor antagonist for depression and relapsing-remitting multiple sclerosis, is being co-developed with Johnson & Johnson under a worldwide exclusive license. Contineum retains U.S. and global rights to PIPE-791 and its discovery portfolio while J&J holds exclusive development and commercialization rights to PIPE-307.
Summary from 10-K filed 2026-03-05
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 |
|---|---|---|---|---|
| Research and development | 52 | 38 | 28 | |
| General and administrative | 17 | 12 | 6 | |
| Total operating expenses | 68 | 51 | 34 | |
| Loss from operations | −68 | −51 | 16 | |
| Interest income | 8 | 9 | 5 | |
| Change in fair value of warrant liability | 0 | −106,000 | 5,000 | |
| Other expense, net | −165,000 | −163,000 | −177,000 | |
| Total other income, net | 8 | 9 | 7 | |
| Net loss | −60 | −42 | 23 | |
| Unrealized gain on marketable securities | 189,000 | −37,000 | 184,000 | |
| Comprehensive loss | −60 | −42 | 23 | |
| Net loss per share, basic (in dollars per share) | −2.17 | −2.18 | 1.36 | |
| Net loss per share, diluted (in dollars per share) | −2.17 | −2.18 | 0.08 | |
| Weighted-average shares of common shares outstanding, basic (in shares) | 28 | 19 | 2 | |
| Weighted-average shares of common shares outstanding, diluted (in shares) | 28 | 19 | 3 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2025 2025-11-30 | FY 2024 2024-12-31 | FY 2024 2024-09-30 | FY 2023 2023-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 76 | — | 22 | — | 16 | |
| Marketable securities | 187 | — | 183 | — | 110 | |
| Prepaid expenses and other current assets | 5 | — | 2 | — | 3 | |
| Total current assets | 268 | — | 206 | — | 128 | |
| Property and equipment, net | 830,000 | — | 989,000 | — | 678,000 | |
| Other long-term assets | 256,000 | — | 3,000 | — | 1 | |
| Operating lease right-of-use assets | 8 | 2 | 5 | 6 | 719,000 | |
| Total assets | 277 | — | 213 | — | 130 | |
| Accounts payable | 1 | — | 2 | — | 635,000 | |
| Accrued expenses | 6 | — | 7 | — | 4 | |
| Current portion of operating lease liabilities | 2 | — | 1 | — | 464,000 | |
| Total current liabilities | 10 | — | 10 | — | 5 | |
| Operating lease liabilities, net of current portion | 6 | — | 5 | — | 108,000 | |
| Total liabilities | 16 | — | 15 | — | 6 | |
| Commitments and contingencies (Note 10) | — | — | — | — | — | |
| Preferred stock, $0.001 par value; authorized shares10,000,000 at December 31, 2025 and December 31, 2024; no shares issued or outstanding at December 31, 2025 and December 31, 2024 | 0 | — | 0 | — | 0 | |
| Additional paid-in-capital | 438 | — | 315 | — | 7 | |
| Accumulated deficit | −177 | — | −117 | — | −75 | |
| Accumulated other comprehensive income | 260,000 | — | 71,000 | — | 108,000 | |
| Total stockholders equity | 261 | — | 198 | — | −68 | |
| Total liabilities and stockholders equity | 277 | — | 213 | — | 130 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 |
|---|---|---|---|---|
| Depreciation and amortization | 300,000 | 300,000 | 200,000 | |
| Non-cash operating lease expense | 1 | 872,000 | 965,000 | |
| Stock-based compensation | 10 | 7 | 2 | |
| Accretion of premiums/discounts on marketable securities, net | −791,000 | −4 | −3 | |
| Loss (gain) on sale of property and equipment | 67,000 | −16,000 | — | |
| Gain on marketable securities | −12,000 | −5,000 | 19,000 | |
| Prepaid expenses and other current assets | −3 | 887,000 | −1 | |
| Other long-term assets | 3,000 | 937,000 | 7,000 | |
| Accounts payable | −869,000 | 1 | 0 | |
| Accrued expenses | −516,000 | 2 | 2 | |
| Operating lease liabilities | −1 | 66,000 | −1 | |
| Net cash used in operating activities | −55 | −33 | 19 | |
| Purchase of property and equipment | −231,000 | −514,000 | −414,000 | |
| Proceeds from sale of equipment | 0 | 20,000 | 0 | |
| Purchases of marketable securities | −163 | −226 | −142 | |
| Sales and maturities of marketable securities | 159 | 157 | 77 | |
| Net cash used in investing activities | −4 | −70 | −66 | |
| Payments of deferred offering costs | −256,000 | 0 | −343,000 | |
| Proceeds from exercise of stock options | 219,000 | 405,000 | 159,000 | |
| Proceeds from employee stock purchase plan | 467,000 | 385,000 | 0 | |
| Net cash provided by financing activities | 113 | 109 | 56 | |
| Net increase in cash and cash equivalents | 54 | 6 | 10 | |
| Property and equipment purchases included in accounts payable | 0 | 58,000 | 30,000 | |
| Reclassification of warrants from liability to equity | 0 | 216,000 | — | |
| Reclassification of deferred offering costs paid in prior year to equity | 0 | 343,000 | — | |
| Right-of-use assets obtained in exchange for lease liabilities | 3 | 6 | 0 |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Contineum Therapeutics, Inc.'s CIK number?
Contineum Therapeutics, Inc.'s SEC CIK number is 0001855175 (1855175). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Contineum Therapeutics, Inc.'s SEC filings?
All of Contineum Therapeutics, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Contineum Therapeutics, Inc. last report earnings?
Contineum Therapeutics, Inc. (CTNM) most recently filed an earnings 8-K with the SEC on May 5, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001628280-26-030522). This is Contineum Therapeutics, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Contineum Therapeutics, Inc.'s most recent earnings 8-K?
Contineum Therapeutics, Inc.'s latest earnings 8-K (Item 2.02) was filed May 5, 2026 under accession 0001628280-26-030522. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Contineum Therapeutics, Inc.'s latest earnings 8-K →
Look up any company's CIK number →